Teucrium Corn Fund vs ResMed Inc. — how do they compare? Teucrium Corn Fund trades at $18.99 (market cap $125.39M), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 254.3× Teucrium Corn Fund's market cap, and ResMed Inc. pays a 1.16% dividend while Teucrium Corn Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Corn Fund for 26 Days and ResMed Inc. for 51 Days on average.
| CORN | RMD | |
|---|---|---|
Market Cap | $125.39M | $31.89B |
Volume | 271,634 | 618,314 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $20.29 | $277.88 |
52-Week Low | $16.46 | $182.82 |
Typical Hold Time | 26 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →